Recent Updates — MDT

Medtronic plc commenced an exchange offer for up to 225,361,295 newly issued shares of MiniMed Group, Inc. common stock in exchange for outstanding Medtronic ordinary shares. The filing corrects a typographical error in the prospectus regarding guaranteed delivery procedures, clarifying that notices expire at 5:00 p.m., New York City time, on the second NYSE trading day after execution rather than midnight. This corporate restructuring separates MiniMed from Medtronic's main entity. Medtronic plc operates in the medical technology industry, designing and manufacturing medical devices.

Medtronic plc reported first quarter fiscal 2027 results ending July 31, 2026, with revenue of $9.8 billion, representing a 13.7% increase as reported and on an organic basis. GAAP diluted EPS was $1.14, while non-GAAP diluted EPS reached $1.45, both exceeding guidance. The company raised its full-year fiscal 2027 organic revenue growth guidance by 50 basis points to a range of 7.25% to 7.75% and increased the diluted non-GAAP EPS guidance to $5.94–$6.00. Cardiovascular portfolio revenue grew 18.9%, driven by strong performance in Cardiac Rhythm Management and Ablation Solutions, while Neuroscience and Medical Surgical segments also posted double-digit organic growth. Medtronic operates as a global leader in healthcare technology, developing medical devices and therapies for cardiovascular, neuroscience, diabetes, and surgical conditions.